IP40 Stock Chart & Stats
€1.48
€0.00(0.00%)
At close: 4:00 PM EDT
€1.48
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€1.28 - €13.20
Previous CloseN/A
Volume0.00
Average Volume (3M)367.00
Market Cap
€6.44M
Enterprise Value€8.16
Total Cash (Recent Filing)€6.44M
Total Debt (Recent Filing)€1.66M
Price to Earnings (P/E)―
Beta-0.45
Next Earnings
Dec 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding4,498,772
10 Day Avg. Volume34
30 Day Avg. Volume367
Financial Highlights & Ratios
PEG Ratio0.48
Price to Book (P/B)3.90
Price to Sales (P/S)0.82
P/FCF Ratio45.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Gross MarginsGross margin near 90% provides a strong economic foundation for cannabinoid products and could support reinvestment in commercialization and pharmaceutical development. If maintained, this profitability at the product level may help the company improve operating results as revenue scale expands.
Moderate LeverageModerate leverage and positive equity provide some financial resilience while InnoCan works toward profitability. The balance sheet is not yet heavily debt-dependent, preserving more flexibility than a highly leveraged structure would provide for funding operations and development.
Losses Have NarrowedThe substantial reduction in losses from earlier periods indicates that the company has made progress toward a more sustainable earnings profile. Although profitability has not been reached, this historical improvement offers evidence that operating performance can improve as products and development programs mature.
Bears Say
Unprofitable And Declining RevenuePersistent operating and net losses, combined with declining trailing revenue, weaken the company’s ability to fund growth internally. Without a return to sustained revenue expansion and positive operating earnings, strong gross margins may not translate into durable cash generation or financial self-sufficiency.
Current Cash BurnNegative operating and free cash flow show that the business is currently consuming cash rather than financing operations from internally generated funds. Continued burn could increase reliance on external funding and limit the resources available for pharmaceutical development and commercial expansion.
Rising Leverage And Negative ReturnsThe increase in debt reliance alongside negative return on equity signals that capital is not yet producing attractive shareholder returns. If losses and cash burn persist, further borrowing could reduce flexibility, increase financial pressure, and make the path to profitability more difficult.
InnoCan Pharma News
IP40 FAQ
What was InnoCan Pharma’s price range in the past 12 months?
InnoCan Pharma lowest stock price was €1.27 and its highest was €13.20 in the past 12 months.
What is InnoCan Pharma’s market cap?
InnoCan Pharma’s market cap is €6.44M.
When is InnoCan Pharma’s upcoming earnings report date?
InnoCan Pharma’s upcoming earnings report date is Dec 02, 2026 which is in 87 days.
How were InnoCan Pharma’s earnings last quarter?
InnoCan Pharma released its earnings results on Aug 31, 2026. The company reported -€0.006 earnings per share for the quarter.
Is InnoCan Pharma overvalued?
According to Wall Street analysts InnoCan Pharma’s price is currently Overvalued.
Does InnoCan Pharma pay dividends?
InnoCan Pharma does not currently pay dividends.
What is InnoCan Pharma’s EPS estimate?
InnoCan Pharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does InnoCan Pharma have?
InnoCan Pharma has 4,498,772 shares outstanding.
What happened to InnoCan Pharma’s price movement after its last earnings report?
InnoCan Pharma reported an EPS of -€0.006 in its last earnings report. Following the earnings report the stock price went up 5.396%.
Which hedge fund is a major shareholder of InnoCan Pharma?
Currently, no hedge funds are holding shares in DE:IP40
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
InnoCan Pharma
InnoCan Pharma Corporation is a pharmaceutical enterprise dedicated to innovating drug delivery systems that integrate cannabidiol (CBD) with other pharmaceutical compounds. Its operations and development efforts span across the United States, Poland, France, and various international markets. The company actively pursues research and development into treatments for conditions such as COVID-19, leveraging CBD delivered via exosomes and liposomes. InnoCan's product line features a range of CBD-infused topical items, including eye serum, face oil, face cream, facial serum, sleeping mask, recovery lotion, and the Relief & Go spray. Beyond R&D, the corporation is also involved in the marketing and distribution of its proprietary CBD-enhanced pharmaceutical and cosmetic offerings. Established in 2018, InnoCan Pharma Corporation maintains its principal office in Calgary, Canada.
Technical Analysis
Willow Biosciences Inc
―
Quantum Biopharma
―
MediPharm Labs
―
Voyageur Pharmaceuticals
―
Avicanna
―